Williams Group | Targeting Disease Pathways in Rheumatoid Arthritis
Research Group, Kennedy Institute
Richard Williams and his team focus on the development of novel therapeutic strategies for chronic inflammatory diseases, like rheumatoid arthritis. He previously focused on the role of TNFα, having successfully contributed to the successful development of anti-TNFα therapy. Subsequent work on combination therapy led to clinical trials of anti-TNFα plus methotrexate, which has set the gold standard for pharmacological management of rheumatoid arthritis.
He was a Senior Lecturer (2007-2011) and then Reader (2011-2012) at Imperial College London and led the Animal Models Group at the Kennedy Institute from 2003-2012.
He led a highly successful MRC DPFS funded project from 2009-2011 and initiated collaborative ventures with numerous pharmaceutical companies, including Merck, Pfizer, GSK, J&J, Bayer-Schering and Celgene.
He has been a Visiting Lecturer at UCL, QMUL and the London School of Hygiene and Tropical Medicine and as an Editor of Arthritis Research and Therapy for many years. He is now on the editorial board of Frontiers in Immunology and Cells and has acted as consultant to many pharmaceutical companies.